Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 65

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 65
---
 a novel technology
related to Nano-Liposomal Particles (NLP). The design and development of these pharmaceutical solutions will consume a large proportion
of our current, as well as projected, resources.

Our research and development costs are comprised
of:

| ● | internal recurring costs,                                                                                                              
 such as personnel-related costs (salaries, employee benefits, equity compensation and other costs), materials and supplies, facilities 
 and maintenance costs attributable to research and development functions; and                                                          |
| ● | fees paid to external parties                                                                                                          
 who provide us with contract services, such as preclinical testing, manufacturing, related testing and preparation for clinical trial  
 activities.                                                                                                                            |

General and Administrative Expenses

General and administrative expenses consist primarily
of salaries, employee benefits, equity compensation and other personnel-related costs associated with executive, administrative and other
support staff. Other significant general and administrative expenses include the costs associated with professional fees for accounting,
auditing, insurance costs, consulting and legal services, along with facility and maintenance costs attributable to general and administrative
functions.

Financial Expenses

Financial expenses consist primarily of the impact
of exchange rates derived from re-measurement of monetary balance sheet items denominated in non-dollar currencies. Other financial expenses
include bank fees and interest on stockholders’ loans.

<div align='center'>37

Results of Operations</div>

Following the closing on July 23, 2024 of the
Share Exchange Agreement with LipoVation whereby LipoVation because a wholly owned subsidiary of Revium Rx, in accordance with ASC 810,
Lipovation’s financial data below are presented as the “Predecessor” for periods prior to the closing of the acquisition.
Revium Rx, which includes consolidation of Lipovation subsequent to the acquisition, is the “Successor” for periods after
the closing of the Business Combination.

As a result of the application of the acquisition
method of accounting in the Successor period, the financial data for the Successor period are presented on a full step-up basis as a
result of the acquisition and are therefore not comparable to the financial statements of the Predecessor period that are not presented
on the same full step-up basis.

Overview

Successor for the nine months period ended September 30, 2025, the Predecessor for the period commencing January 1 through July 23, 2024 and Successor for the period commencing July 24 through September 30, 2024

The following tables present selected financial
data for